Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1 | Zendy

AI Assistant Blog Pricing

Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.